{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:39:38Z","timestamp":1759451978100,"version":"build-2065373602"},"reference-count":29,"publisher":"Georg Thieme Verlag KG","issue":"01","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Klin Monbl Augenheilkd"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\n               Background Diabetic macular oedema (DME) is associated with significant loss of visual acuity. Intravitreal VEGF inhibitor injection is the gold standard in treating this disease; second-line treatment consists of intravitreal steroid injections. This treatment has already undergone extensive investigation in large randomised controlled trials. The aim of this study is to evaluate patient population and treatment options in a real-world setting.<\/jats:p><jats:p>\n               Material and Methods A retrospective analysis was conducted on data from 176 eyes in 114 patients diagnosed with diabetic macular oedema who had received at least one intravitreal injection during 2018 at Marburg University Hospital Department of Ophthalmology. The analysis examined demographic characteristics, prior treatment, and treatments performed as well as visual acuity and central retinal thickness development during therapy. Multiple linear regression analyses were used to investigate the influence of different variables on changes in dependent variables in visual acuity (logMAR), changes in retinal thickness (\u00b5m), and number of injections, while also taking interactions between the independent variables themselves into account.<\/jats:p><jats:p>\n               Results Patients were on average 64.45\u2009\u00b1\u200913.79 years old and predominantly male (61.93%). Most (71.59%) had already been treated for DME. Baseline visual acuity averaged 0.42\u2009logMAR\u2009\u00b1\u20090.34; baseline central retinal thickness averaged 369.1\u2009\u00b5m\u2009\u00b1\u2009118.81. A total of 688 intravitreal injections were administered at 3.91\u2009\u00b1\u20092.22 per eye during the study period. Visual acuity improved by 0.04\u2009logMAR\u2009\u00b1\u20090.18 on average; eyes with poorer baseline visual acuity showed a greater increase in visual acuity. CRT values decreased by 44.54\u2009\u00b5m\u2009\u00b1\u2009133.95 on average. Eyes with higher baseline values showed greater reduction. Using regression analysis, this is the first study to demonstrate that eyes may continue to require additional injections after prior treatment.<\/jats:p><jats:p>\n               Conclusion This study demonstrated the reality of treatment for patients with diabetic macular oedema at a German university clinic as accurately as possible. We were able to demonstrate the differences from RCTs and the characteristics of the patient cohort.<\/jats:p>","DOI":"10.1055\/a-2419-1794","type":"journal-article","created":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T18:43:26Z","timestamp":1731955406000},"page":"22-30","source":"Crossref","is-referenced-by-count":0,"title":["Diabetic Macular Oedema \u2013 Patient Characteristics and the Reality of Treatment in a German University Hospital"],"prefix":"10.1055","volume":"242","author":[{"given":"Anna Mareike","family":"Eder","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Augenheilkunde, Universit\u00e4tsklinikum Gie\u00dfen und Marburg \u2013 Standort Marburg, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter","family":"Sekundo","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Augenheilkunde, Universit\u00e4tsklinikum Gie\u00dfen und Marburg \u2013 Standort Marburg, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Volker","family":"Besgen","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Augenheilkunde, Universit\u00e4tsklinikum Gie\u00dfen und Marburg \u2013 Standort Marburg, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Schulze","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Augenheilkunde, Universit\u00e4tsklinikum Gie\u00dfen und Marburg \u2013 Standort Marburg, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2024,11,18]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"556","DOI":"10.2337\/dc11-1909","article-title":"Global prevalence and major risk factors of diabetic retinopathy","volume":"35","author":"J W Yau","year":"2012","journal-title":"Diabetes Care"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0161-6420(84)34337-8","article-title":"Visual impairment in diabetes","volume":"91","author":"R Klein","year":"1984","journal-title":"Ophthalmology"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1159\/000438970","article-title":"Diabetic Retinopathy and Diabetic Macular Edema","volume":"55","author":"S R Cohen","year":"2016","journal-title":"Dev Ophthalmol"},{"key":"ref4","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-662-59154-3","volume-title":"Augenheilkunde","author":"F Grehn","year":"2019","edition":"32. Aufl."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"489","DOI":"10.4239\/wjd.v6.i3.489","article-title":"Diabetic retinopathy \u2013 ocular complications of diabetes mellitus","volume":"6","author":"M M Nentwich","year":"2015","journal-title":"World J Diabetes"},{"key":"ref6","first-page":"259","article-title":"Diabetic retinopathy","volume":"1","author":"F T Shaya","year":"2007","journal-title":"Clin Ophthalmol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.2337\/diacare.27.5.1047","article-title":"Global prevalence of diabetes: estimates for the year 2000 and projections for 2030","volume":"27","author":"S Wild","year":"2004","journal-title":"Diabetes Care"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"4731","DOI":"10.2174\/1381612821666150909095756","article-title":"Anti-VEGF Molecules for the Management of Diabetic Macular Edema","volume":"21","author":"F Bandello","year":"2015","journal-title":"Curr Pharm Des"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1177\/2042018813512360","article-title":"Anti-vascular endothelial growth factor therapy for diabetic macular edema","volume":"4","author":"D S Boyer","year":"2013","journal-title":"Ther Adv Endocrinol Metab"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.phrs.2015.11.003","article-title":"Pathophysiology and pharmacological targets of VEGF in diabetic macular edema","volume":"103","author":"S Fogli","year":"2016","journal-title":"Pharmacol Res"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1159\/000458539","article-title":"Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA)","volume":"237","author":"U Schmidt-Erfurth","year":"2017","journal-title":"Ophthalmologica"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1016\/j.ophtha.2014.04.024","article-title":"Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema","volume":"121","author":"D S Boyer","year":"2014","journal-title":"Ophthalmology"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.jphs.2018.11.001","article-title":"Long-term efficacy and safety profile of multiple injections of intravitreal dexamethasone implant to manage diabetic macular edema: A systematic review of real-world studies","volume":"138","author":"C Bucolo","year":"2018","journal-title":"J Pharmacol Sci"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1159\/000458539","article-title":"Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA)","volume":"237","author":"U Schmidt-Erfurth","year":"2017","journal-title":"Ophthalmologica"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1016\/j.ophtha.2015.06.017","article-title":"Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies","volume":"122","author":"D M Brown","year":"2015","journal-title":"Ophthalmology"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/j.ophtha.2010.03.045","article-title":"A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2","volume":"117","author":"M Michaelides","year":"2010","journal-title":"Ophthalmology"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.ophtha.2011.01.031","article-title":"The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema","volume":"118","author":"P Mitchell","year":"2011","journal-title":"Ophthalmology"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","article-title":"Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE","volume":"119","author":"Q D Nguyen","year":"2012","journal-title":"Ophthalmology"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.ophtha.2016.02.022","article-title":"Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial","volume":"123","author":"J A Wells","year":"2016","journal-title":"Ophthalmology"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1016\/j.ophtha.2012.04.030","article-title":"Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema","volume":"119","author":"P A Campochiaro","year":"2012","journal-title":"Ophthalmology"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1007\/s13300-018-0513-2","article-title":"Intravitreal Ranibizumab Therapy for Diabetic Macular Edema in Routine Practice: Two-Year Real-Life Data from a Non-interventional, Multicenter Study in Germany","volume":"9","author":"F Ziemssen","year":"2018","journal-title":"Diabetes Ther"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"e942","DOI":"10.1111\/aos.13771","article-title":"A noninterventional study to monitor patients with diabetic macular oedema starting treatment with ranibizumab (POLARIS)","volume":"96","author":"J Stefanickova","year":"2018","journal-title":"Acta Ophthalmol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"5376","DOI":"10.1007\/s12325-022-02326-8","article-title":"Outcomes of Over 40,000 Eyes Treated for Diabetic Macula Edema in Routine Clinical Practice: A Systematic Review and Meta-analysis","volume":"39","author":"H Mehta","year":"2022","journal-title":"Adv Ther"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"4610129","DOI":"10.1155\/2018\/4610129","article-title":"Treatment Efficacy and Compliance in Patients with Diabetic Macular Edema Treated with Ranibizumab in a Real-Life Setting","volume":"2018","author":"A L Best","year":"2018","journal-title":"J Ophthalmol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2147\/OPTH.S154421","article-title":"Aflibercept for clinically significant diabetic macular edema: 12-month results in daily clinical practice","volume":"12","author":"R Campos Polo","year":"2018","journal-title":"Clin Ophthalmol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1136\/bjophthalmol-2020-315933","article-title":"Visual acuity outcomes and anti-VEGF therapy intensity in diabetic macular oedema: a real-world analysis of 28 658 patient eyes","volume":"105","author":"T A Ciulla","year":"2021","journal-title":"Br J Ophthalmol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"393","DOI":"10.2147\/OPTH.S128509","article-title":"Anti-VEGF treatment of diabetic macular edema in clinical practice: effectiveness and patterns of use (ECHO Study Report 1)","volume":"11","author":"K J Blinder","year":"2017","journal-title":"Clin Ophthalmol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/eye.2015.246","article-title":"Dexamethasone implant in diabetic macular edema in real-life situations","volume":"30","author":"J Chhablani","year":"2016","journal-title":"Eye (Lond)"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1016\/j.ophtha.2014.05.006","article-title":"Intravitreal aflibercept for diabetic macular edema","volume":"121","author":"J F Korobelnik","year":"2014","journal-title":"Ophthalmology"}],"container-title":["Klinische Monatsbl\u00e4tter f\u00fcr Augenheilkunde"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2419-1794.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T23:56:26Z","timestamp":1759362986000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2419-1794"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,18]]},"references-count":29,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2025,1,16]]},"published-print":{"date-parts":[[2025,1]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2419-1794","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0023-2165","1439-3999"],"issn-type":[{"type":"print","value":"0023-2165"},{"type":"electronic","value":"1439-3999"}],"subject":[],"published":{"date-parts":[[2024,11,18]]}}}